

TARGET[®] First Lite

Designed for Precision, Priced with Compassion.

Focused 87 genes DNA biomarker panel for routine precision oncology practice in the treatment of locally advanced solid tumors.



Making Precision Oncology Accessible For All

DESIGNED FOR PRECISION. PRICED WITH COMPASSION.

WHY TARGET FIRST LITE?



Focused Genomic Profiling for Routine Oncology Practice:

Designed for newly diagnosed and locally advanced solid tumors.



Beyond Single-Gene Testing:

Simultaneously evaluates multiple clinically relevant biomarkers, eliminating the limitations of sequential testing.



Comprehensive Biomarker Coverage:

Detects alterations across 87 cancer-associated genes and 72 clinically relevant copy number alterations (CNAs).



Actionable Clinical Insights:

Identifies biomarkers linked to FDA-approved and NCCN-recommended targeted therapies.



Supports Precision Treatment Decisions:

Enables the detection of predictive biomarkers relevant for therapy selection and patient stratification.



High Clinical Utility, Lower Cost:

Delivers meaningful genomic insights through an affordable and accessible testing approach.




Rapid Turnaround for Timely Decisions:

Optimized for efficient reporting to support treatment planning without delays.



Democratizing Precision Oncology:

Makes comprehensive biomarker testing accessible to a broader patient population.



Key Genes in TARGT First Lite Associated with Therapeutic Options



Cancer Type	Key Genes Covered
Breast Cancer	<i>BRCA1, BRCA2, PIK3CA, ERBB2, ESR1, AKT1, PTEN, PALB2, ATM, CHEK2</i>
Ovarian Cancer	<i>BRCA1, BRCA2, PALB2, ATM, RAD51, RAD51C, RAD51D, BRIP1, FANCA</i>
Endometrial Cancer	<i>PTEN, PIK3CA, PIK3R1, KRAS, TP53, POLE, MLH1, MSH2, MSH6, PMS2, ERBB2</i>
Cervical Cancer	<i>PIK3CA, ERBB2, PTEN, KRAS</i>
Prostate Cancer	<i>BRCA1, BRCA2, ATM, PALB2, CHEK2, AR, PTEN, RB1</i>
Lung Cancer	<i>EGFR, KRAS, BRAF, ERBB2, MET, PIK3CA, STK11, RET, ROS1</i>
Colorectal Cancer	<i>KRAS, NRAS, BRAF, PIK3CA, APC, ERBB2, SMAD4</i>
Gastric / GEJ	<i>ERBB2, PIK3CA, KRAS, FGFR2, MET</i>
Pancreatic Cancer	<i>KRAS, BRCA1, BRCA2, PALB2, ATM, SMAD4</i>
Cholangiocarcinoma	<i>IDH1, IDH2, KRAS, BRAF, ERBB2, FGFR2</i>
Head & Neck Cancer	<i>PIK3CA, HRAS, CDKN2A, CCND1, EGFR</i>
Glioma / CNS	<i>IDH1, IDH2, ATR, EGFR, PTEN</i>

Note : For fusion-driven cancers or when clinically indicated, TARGT First may be recommended.

Performance Matrix, Sample Type and Turn-around Time



Gene Number

87 Genes



Sample Type

FFPE Tissue block ideally not more than 5 months old,
Fresh Frozen Tissue, with > 20% Tumor content



Specificity and Sensitivity

99.99%



Turn Around Time

12-14 working days



Sequencing Chemistry

Hybrid Capture, End to End Sequencing of all the
Exons of a given Gene



Mean Sequencing Depth

2000X

Revolutionising Care, Personalising Hope Globally

With Precision Oncology, we're not just treating cancer.
We're redefining what's possible in Cancer care.

Together, **We Beat** Cancer



● India ● Nepal ● Philippines ● UAE



For any further information on 4baseCare Solutions and Services, please contact:

🌐 4basecare.com 📞 +91 636-684-3415 ✉ info@4basecare.com

📍 3rd floor, Summit B, Brigade Metropolis, Garudachar Palya, Bengaluru, Karnataka 560048